CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Gleevecdrug
Likely dose
Gleevec 440 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01673009
NCT01673009Phase 2Completed
CompareCT.gov

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Indiana University·interventional·Posted Aug 27, 2012·Updated Apr 6, 2016

In Brief

A Phase 2 clinical trial evaluating Gleevec for Neurofibromatosis. Completed, enrolled 36 participants across 1 site.

Detailed Summary

THe primary objective is to estimate the response rate at 6 months to Gleevec® in patients with plexiform neurofibromas

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 27, 2012
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2011
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 13.8 years ago

Interventions

Gleevecdrug

Gleevec® will be dosed orally 440 mg/m\^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.